Ju Fu Tang Biotech Holdings , Ltd EBIT

The latest EBIT for 8217.HK is $14M as of March 2026. That compares with $-7M in the prior-year period — up 306.4% year over year. That is below the Industrials sector average of $160B. Investors often review this figure alongside Ju Fu Tang Biotech Holdings , Ltd's historical trend and sector peers before judging valuation or financial health.

Over the past year, 8217.HK's EBIT moved from $-7M to $14M — a 306.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Ju Fu Tang Biotech Holdings , Ltd's operating scale or balance-sheet position.

Against Industrials companies, 8217.HK currently prints $14M for EBIT, while the sector average sits near $160B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Ju Fu Tang Biotech Holdings , Ltd's growth, margins, and balance sheet.

A EBIT figure of $14M for 8217.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Industrials average is about $160B. Explore the charts below for those layers of context.

After noting 8217.HK's EBIT ($14M), review year-over-year change from $-7M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.